Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C53D | ISIN: US78163D1000 | Ticker-Symbol:
NASDAQ
16.01.25
19:35 Uhr
11,410 US-Dollar
+0,030
+0,26 %
1-Jahres-Chart
RUNWAY GROWTH FINANCE CORP Chart 1 Jahr
5-Tage-Chart
RUNWAY GROWTH FINANCE CORP 5-Tage-Chart
GlobeNewswire (Europe)
48 Leser
Artikel bewerten:
(0)

Runway Growth Finance Corp. Provides Fourth Quarter 2024 Portfolio Update

Finanznachrichten News
  • Completed Seven Investments in New and Existing Portfolio Companies Representing $154 Million in Funded Loans

MENLO PARK, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the fourth quarter ended December 31, 2024.

"Runway Growth closed out 2024 with seven investments in new and existing portfolio companies in the high growth target sectors of technology, healthcare and consumer services," said David Spreng, Founder and CEO of Runway Growth. "Our underlying borrowers generally continue to perform well, driving strength in our existing portfolio. Looking ahead, we are focused on expanding and diversifying our financing solutions. Runway Growth Capital LLC, the investment adviser to Runway Growth, is on track to close its proposed business combination with BC Partners in the first quarter of 2025, and we are positioned to leverage our combined scale and resources to accelerate originations. Our team is energized as we seek to capitalize on attractive investment opportunities that we believe will benefit our shareholders with enhanced growth drivers for long-term returns."

Originations
In the fourth quarter of 2024, Runway Growth funded seven investments: two investments in new portfolio companies and five investments in existing portfolio companies. These include:

  • Completion of a new $41 million investment to existing portfolio company VTX Holdings, LLC dba VertexOne ("VertexOne"), funding the full $41 million at close, which refinanced VertexOne's existing senior term loan;
  • Completion of a new $40 million investment to existing portfolio company Brivo Systems, LLC ("Brivo"), funding the full $40 million at close, which refinanced Brivo's existing senior term loan;
  • Completion of a new $43.0 million investment to Piano Software, Inc. ("Piano"), funding the full $43.0 million at close. Piano is a global leader in digital experience management, customer journey orchestration, and advanced analytics;
  • Completion of a new $26.7 million investment to Hurricane CleanCo Limited ("Hurricane CleanCo"), funding the full $26.7 million at close. Hurricane CleanCo operates an integrated merchant acquiring and payment processing platform focused on SMB and Enterprise merchants; and
  • Completion of follow-on investments with an aggregate amount of $3.3 million to three existing portfolio companies.

Liquidity Events
During the fourth quarter ended December 31, 2024, Runway Growth experienced the following liquidity events:

  • Full principal repayment of the Company's senior secured term loan to VertexOne of $91.7 million;
  • Full principal repayment of the Company's senior secured term loan to Brivo of $32.3 million;
  • Full principal repayment of the Company's senior secured term loan to Predactiv, Inc. (fka Sharethis, Inc.) of $18.5 million;
  • Full principal repayment of the Company's senior secured term loan to Betterment Holdings, Inc. of $8.0 million;
  • Partial principal repayment of the Company's senior secured term loan to FiscalNote Holdings, Inc. of $2.1 million;
  • Other scheduled principal amortization of $2.4 million; and
  • During the fourth quarter, the Company liquidated its holdings in Dtex Systems, Inc. preferred stock for total proceeds of $1.9 million.

Portfolio Construction and Management
Runway Growth is a credit-first organization, carefully structured to focus on what it believes to be the highest quality, late-stage companies in the venture debt market. The Company seeks to uphold industry-leading investment standards as well as disciplined underwriting and monitoring of its portfolio. Runway Growth is positioned as a preferred lender in the venture debt space, supporting and working closely with companies to help them reach their full growth potential. Since inception, the Company has focused on the fastest growing sectors of the economy, including healthcare, technology and select consumer services and products industries.

As of December 31, 2024, the Runway Growth portfolio included 47 debt investments to 32 portfolio companies and 88 equity investments in 53 portfolio companies, including 28 portfolio companies where Runway Growth holds both a debt and equity investment. Investments were comprised of late and growth-stage businesses in the technology, healthcare and consumer services and products industries. Runway Growth's normal business operations include frequent communication with portfolio companies.

About Runway Growth Finance Corp.
Runway Growth is a growing specialty finance company focused on providing flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity. Runway Growth is a closed-end investment fund that has elected to be regulated as a business development company under the Investment Company Act of 1940. Runway Growth is externally managed by Runway Growth Capital LLC, an established registered investment advisor that was formed in 2015 and led by industry veteran David Spreng. For more information, please visit www.runwaygrowth.com.

Forward-Looking Statements
Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Runway Growth's filings with the Securities and Exchange Commission. Runway Growth undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Important Disclosures
Strategies described involve special risks that should be evaluated carefully before a decision is made to invest. Not all of the risks and other significant aspects of these strategies are discussed herein. Please see a more detailed discussion of these risk factors and other related risks in the Company's most recent annual report on Form 10-K in the section entitled "Risk Factors", which may be obtained on the Company's website, www.runwaygrowth.com, or the SEC's website, www.sec.gov.

IR Contacts:
Taylor Donahue, Prosek Partners, rway@prosek.com
Thomas B. Raterman, Chief Financial Officer and Chief Operating Officer, tr@runwaygrowth.com


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.